Varian Medical (NYSE:VAR) yesterday released its fiscal Q3 earnings and announced it acquired Netherlands-based X-ray component manufacturer Claymount for $55 million (€50 million). The Palo Alto, Calif.-based company grew from Q3 last year but failed to meet the street on earnings and revenue. Varian reported $1.13 earnings per share for the quarter, an 11¢ increase since […]
Varian Medical Systems
Varian books $87m order on Maryland proton therapy center
Varian to expand in Atlanta, adding 100 jobs
Varian nabs German cancer screening software maker MeVis Medical
Patent battle takes a chunk out of Varian’s bottom line
Radiosurgery devices maker Varian Medical (NYSE:VAR) posted a tough quarter, with sales up a modest 1.3% and earnings sucked up by legal charges in its 2nd quarter.
Varian settles patent beef with Pitt for $35M
Varian Medical (NYSE:VAR) said it settled its patent infringement beef with the University of Pittsburgh for $35 million, after a federal appeals court overturned a portion of the $100 million award Pitt won in 2012.
Varian closes stealthy acquisition of Velocity cancer-management software
California device maker Varian Medical (NYSE:VAR) remained tight-lipped about its bid for software maker Velocity Medical Solutions as it announced the acquisition’s close today.
Varian to acquire cancer software maker Velocity Medical
Varian Medical (NYSE:VAR) said it inked a deal to acquire Velocity Medical Solutions’ cancer clinic software.
Medtech personnel moves for the week of Mar. 10, 2014
ConMed proxy war gets ugly
February 28, 2014 by Brad Perriello
The proxy war over control of the board at ConMed turned ugly this week after serious allegations surfaced against 1 of the medical device company’s nominees for director.
Medtronic vet takes over marketing at Vexim | Personnel Moves
Varian misses analysts’ estimates but is on track for 2014
Palo Alto, Calif.-based Varian Medical (NYSE:VAR) started its fiscal year with moderate growth and a reaffirmed outlook on 2014, but per-share earnings fall short of analysts’ projections.